Antegren: Shaking Up the MS Market?
Executive Summary
The dynamics of specialty chronic care markets suggest that Biogen Idec and Elan's highly anticipated Antegren may have trouble turning the scrappy $3.5 billion MS market on its head, at least right away.
You may also be interested in...
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
Drug Safety, the Sequel: This Time It's Specialist Products
The withdrawal of Biogen Idec Inc. and Elan Corp.'s natalizumab (Tysabri) multiple sclerosis treatment just weeks after its introduction showed that specialist products aren't immune from serious safety issues. Sales and clinical trials of the drug were suspended with the cooperation of the FDA after two patients in the companies' clinical study of Tysabri in combination with Avonex developed the rare and often fatal demyelinating disorder PML.